<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309139</url>
  </required_header>
  <id_info>
    <org_study_id>1298.2</org_study_id>
    <secondary_id>2010-023780-18</secondary_id>
    <nct_id>NCT01309139</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers</brief_title>
  <official_title>An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat® B Versus the Combination of the Monoproducts of Tiotropium Via Respimat® A and BI 54903 Via Respimat® B in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to compare the systemic exposure to tiotropium and CD 1857 after
      treatment with the fixed dose combination (fixed dose combination (FDC), Treatment A) of
      tiotropium plus BI 54903 (ethanolic solution for inhalation (EIS), Respimat (RMT) B) with the
      systemic exposure following inhalation of the free combination (Treatment B) of tiotropium
      (aqueous solution for inhalation (AIS), RMT A) plus BI 54903 (EIS, RMT B), when administered
      once-daily over 21 days via Respimat(R) (RMT).

      The secondary objectives are:

      to compare the systemic exposure to tiotropium and CD 1857 after single dose administration
      of FDC and of the free combination of tiotropium/BI 54903 to compare the systemic exposure to
      BI 54903 after a single dose and at steady state after multiple doses of the FDC and of the
      free combination of tiotropium/BI 54903 to compare the safety and tolerability of tiotropium
      and BI 54903 when administered as FDC and as free dose combination, respectively
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration time curve of CD 1857 in plasma over a uniform dosing interval τ (AUCτ,ss)</measure>
    <time_frame>on several time points until day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of CD 1857 in plasma at steady state (Cmax,ss)</measure>
    <time_frame>on several time points until day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss for Tiotropium</measure>
    <time_frame>on several time points until day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss for Tiotropium</measure>
    <time_frame>on several time points until day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss for BI 54903</measure>
    <time_frame>on several time points until day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss for BI 54903</measure>
    <time_frame>on several time points until day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-24 (Amount of analyte that is eliminated in urine) for tiotropium</measure>
    <time_frame>on Day 1 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical examination</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-lead electrocardiogram</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory tests</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by the investigator</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: Tiotropium medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral inhalation daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A: BI 54903 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral inhalation daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Tiotropium medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral inhalation daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: BI 54903 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral inhalation daily for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Medium dose of oral inhalation</description>
    <arm_group_label>Treatment A: Tiotropium medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Medium dose of oral inhalation</description>
    <arm_group_label>Treatment B: Tiotropium medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 54903</intervention_name>
    <description>Medium dose of oral inhalation</description>
    <arm_group_label>Treatment C: BI 54903 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 54903</intervention_name>
    <description>Medium dose of oral inhalation</description>
    <arm_group_label>Treatment A: BI 54903 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (blood pressure (BP),
             pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests.

          2. Age 21 to 50 years.

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. History or evidence of relevant psychiatric disorders or neurological disorders

          5. History or evidence of relevant autonomic dysfunction (orthostatic hypotension,
             fainting spells or blackouts)

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          8. Intake of any prescription drugs or over-the-counter (over the counter (OTC))
             medication (vitamins, herbal supplements, dietary supplements) with a long half-life
             (&gt; 24 hours) within at least one month or less than 10 half-lives of the respective
             drug prior to administration or during the trial

          9. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         10. Smoker (more than 10 cigarettes daily)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1298.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

